Devonian Health Group, Inc. · TSXV:GSD
Devonian Health — Investor Presentation (December 2022)
33 slides from Devonian Health's investor presentation, December 2022
Slide 1: Corporate Presentation December 2022
CORPORATE PRESENTATION December 2022 TSXv – GSD OTCQB – DVHGF Farm to PharmTM 1 1
Slide 2: Cautionary Statements
Cautionary Statements This corporate presentation (“Presentation”) has been prepared by DEVONIAN HEALTH GROUP INC. (“DEVONIAN”) with market information provided by number of factors. various third-party sources which we believe are reliable and is being furnished solely for the purpose of considerin
Slide 3: Corporate Snapshot
Corporate Snapshot Farm to PharmTM TSXv : GSD / OTCQB : DVHGF 3
Slide 4: Devonian Health Group Snapshot
Devonian Health Group Snapshot A Leader in the Discovery, Research & Principal Asset Thykamine™ ready to embark on Development (R&D) of Botanical Drugs / Pharmaceuticals (prescriptions) following US-FDA, Phase 3 trial for mid-to-moderate Adult Atopic Germany-BfArM, and Health Canada Regulations Derm
Slide 5: Strong Leadership And Advisory Boards
Strong Leadership And Advisory Boards Management Pierre Montanaro Dr André P. Boulet, PhD Sybil Dahan, BSc. Colette Laurin CPA, CA Dr Mostafa Akbarieh, PhD Dr Daniel Bouthillier, PhD President & CEO Chief Scientific Officer President, Altius Healthcare CFO VP Regulatory Affairs VP Research Burroughs
Slide 6: State-of-the-Art Pharmaceutical grade (cGMP) Extraction Facility
State-of-the-Art Pharmaceutical grade (cGMP) Extraction Facility PROCESSING FACILITY • 1,625 square meters • Located in Montmagny (Québec) • Water system upgradable to produce injectables / sterile eye solutions PHARMACEUTICAL GRADE • Full scale facility with custom designed equipment • Full traceab
Slide 7: Unique Proprietary Technology
Unique Proprietary Technology protected by Patents and Industrial secrets SOURCING EXTRACTION DEVELOPMENT BOTANICALS of ACTIVE BOTANICAL INGREDIENTS (ABI) with SUPREX™ of RX BOTANICAL DRUGS (Botanical complexes) And COSMECEUTICALS SUPREX™ Process Thykamine™ Organic Baby Spinach Extraction and Proces
Slide 8: Botanical Drug regulations
Botanical Drug regulations Less costly and condensed R&D program allowing for quick-to-market NEXT WAVE IN PHARMACEUTICALS BENEFITS OVER CHEMICALLY SYNTHESISED DRUGS ▪ Specific FDA regulations: Botanical Drug ▪ Faster preclinical development, and as robust Regulations clinical program as for traditi
Slide 9: Devonian's Target Therapeutic Areas and Indications
Devonian’s Target Therapeutic Areas and Indications in high value markets GLOBAL MARKET THERAPEUTIC INDICATIONS (Forecasted by 2026) Atopic Dermatitis (Eczema) US $21Bn1 15-30% of children Leadership Position Opportunity Ulcerative Colitis (Inflammatory Bowel Disease) US $10 Bn4 0.2% of population R
Slide 10: R&D Program set for Phase 3 trial
R&D Program set for Phase 3 trial In preparation for first entry into Market DRUG DEVELOPMENT PIPELINE WITHIN A PRODUCT DERMATOLOGY Indication Preclinical Phase 1 Phase 2 Phase 3 Atopic Dermatitis (Adult - Topical) Atopic Dermatitis (Pediatric - Topical) Hand and Foot Syndrome associated to Chemothe
Slide 11: Pipeline In A Product: Ulcerative Colitis Phase 2a
Pipeline In A Product Thykamine™️: Inflammation under Control • Ulcerative Colitis Phase 2a Proof of Concept Study Farm to PharmTM TSXv : GSD / OTCQB : DVHGF 11
Slide 12: Rectal Bleeding Sub-Score
Positive impact on Ulcerative Colitis symptoms (UC) in Phase 2 (proof of concept) trial Clinical Symptoms (1) Rectal Bleeding – Modified Mayo Sub-Score 0 Patients with left- Placebo Day 7 Day 14 Day 21 -0.2 sided Mid-to- (n=5) Mean Change from Baseline in Moderate Ulcerative Colitis -0.4 Rectal Blee
Slide 13: Outstanding Anti-Inflammatory effect at day 21 in UC patients
Outstanding Anti-Inflammatory effect at day 21 in UC patients Biomarkers 60 40 20 % 0 -20 -40 -60 * Placebo Thykamine™ 250 mg/day -80 -100 * * P ˂ 0.05 (1) A 2-Week Exploratory Randomized, Double-Blind, Parallel- Group, Dose-Ranging, Placebo-Controlled Safety, Tolerability, Biomarker and Efficacy Cl
Slide 14: Thykamine - Inflammation under Control - Ulcerative Colitis
Thykamine™️ - Inflammation under Control - Ulcerative Colitis ▪ Phase 2a P.O.C. Clinical Study in patients with mild-to-moderate distal ulcerative colitis (2) • Rectal enema : Placebo, 250, 500 and 1500mg O/D for 14 days • Safe and well tolerated • Approx.1 point placebo-corrected improvements in th
Slide 15: Pipeline In A Product
Pipeline In A Product Potential to study Thykamine™️: Corporate Focus on Dermatological inflammatory disorders • Atopic Dermatitis ➢ Adult ➢ Pediatric • Hand & Foot Syndrome associated to Chemotherapy • Radiodermatitis associated to Radiotherapy Farm to PharmTM TSXv : GSD / OTCQB : DVHGF 15
Slide 16: Adult Atopic Dermatitis (AD) Phase 2 Trial
Adult Atopic Dermatitis (AD) Phase 2 Trial 1 Setting Stage for Phase 3 PRIMARY ENDPOINT Proportion of patients with an IGA score of 0 (clear) or 1 (almost clear) and with at least a 2-grade improvement in IGA score Placebo from baseline (n=40) Day 7 Day 14 Day 21 Day 29 Adult Patients with Mid-to- S
Slide 17: Adult Atopic Dermatitis (AD) Phase 2 Trial
Adult Atopic Dermatitis (AD) Phase 2 Trial 1 Setting Stage for Phase 3 Proportion of patients achieving Primary Endpoint : IGA 0 or 1 and 2-point Reduction from Baseline 35.0 30.8 * 30.0 25.0 * 23.1 20.0 19.0 % 15.4 15.0 12.1 9.8 10.0 6.7 5.3 5.0 4.0 2.9 2.9 2.8 2.3 0.0 0.0 0.0 0.0 Day 7 Day 14 Day
Slide 18: Adult Atopic Dermatitis (AD) Phase 2 Trial
Adult Atopic Dermatitis (AD) Phase 2 Trial 1 Setting Stage for Phase 3 Proportion of patients achieving secondary endpoint : IGA 0 or 1 50.0 * 46.2 45.0 40.0 * * 35.9 35.0 33.3 33.3 30.0 26.8 24.2 % 25.0 19.0 19.4 20.0 15.8 15.0 13.6 10.0 8.6 8.8 8.1 8.0 7.0 5.3 5.0 0.0 Day 7 Day 14 Day 21 Day 29 Ve
Slide 19: Adult Atopic Dermatitis Phase 2 Trial Setting Stage for Phase 3
1 Adult Atopic Dermatitis (AD) Phase 2 Trial Setting Stage for Phase 3 Mean change in key secondary endpoints by treatment group over time. A: Change in % BSA affected B: Change in Pruritus C: Change in DLQI score D: Change in POEM score a: p ≤ .05 vs baseline b: p ≤ .01 vs baseline c: p ≤ .001vs ba
Slide 20: Adult Atopic Dermatitis (AD) Phase 2 Trial
Adult Atopic Dermatitis (AD) Phase 2 Trial 1 Setting Stage for Phase 3 Incidence of AEs, n (%) that were probably, possibly, or definitely related to study medication (safety population). PUR 0110 PUR 0110 PUR 0110 Severity Adverse event Vehicle (n=40) 0.05% 0.10% 0.25% (n=44) (n=39) (n=39) Eye diso
Slide 21: Adult Atopic Dermatitis Phase 2 Trial Competitive Landscape
Adult Atopic Dermatitis (AD) Phase 2 Trial Competitive Landscape Competitive landscape vs new chemical entities Efficacy rate similar to drugs derived from chemical synthesis % Patients reaching primary Drug Mechanism of action Clinical development phase Patient population endpoint (p<0.05) Thykamin
Slide 22: Thykamine - Best-In-Class Potential
Thykamine™ – Best-In-Class Potential Targeting unmet needs in autoimmune and inflammatory diseases • Compelling efficacy from Phase 2 clinical study in Adult population with Mild-to-Moderate Atopic Dermatitis (AD) • Fast onset of action • Efficacy on AD similar to biotech products issued from chemic
Slide 23: Thykamine: All in place to go from Farm to Pharm
Thykamine™️ All in place to go from Farm to Pharm™️ Farm to PharmTM TSXv : GSD / OTCQB : DVHGF 23
Slide 24: Radiotherapy Supportive Care
Radiotherapy Supportive Care Farm to PharmTM TSXv : GSD / OTCQB : DVHGF 24
Slide 25: Radiodermatitis associated to Radiotherapy
Radiodermatitis associated to Radiotherapy An unmet Medical Need (1,2,3) ▪ In North America, Europe and Australia : 50% of patients diagnosed with cancer will receive radiation therapy during their illness — 90% of these patients will develop some degree of radiodermatitis (radiation-induced skin re
Slide 26: Chemotherapy Supportive Care
Chemotherapy Supportive Care Farm to PharmTM TSXv : GSD / OTCQB : DVHGF 26
Slide 27: Hand & Foot Syndrome Associated To Chemotherapy
Hand & Foot Syndrome Associated To Chemotherapy An Unmet Medical Need (1,2,3,4,5,6) ▪ Hand & Foot syndrome (HFS), also known as palmoplantar erythrodysesthesia or acral erythema, is a well- documented adverse effect of numerous chemotherapeutic agents. • Inflammatory response at the Hand and Foot le
Slide 28: Corporate IP
Corporate IP Farm to PharmTM TSXv : GSD / OTCQB : DVHGF 28
Slide 29: Intellectual Property Portfolio
Intellectual Property Portfolio U.S. and international patent Indications Four (4) Trade marks estate covering • Extraction / Isolation / stabilization process • Inflammation • Devonian TM • Composition • Cardiovascular • Fram to Pharm TM • Route of Administration (oral; iv; ip; etc.) • Gastrointest
Slide 30: Key Anticipated Milestones Within Next 24 Months
KEY ANTICIPATED MILESTONES WITHIN NEXT 24 MONTHS Phase 2 Pediatric Atopic Dermatitis Top-line results ✓ Phase 2 POC Hand & Foot Syndrome Top-line results ✓ Phase 2 POC Radiodermatitis Top-line results ✓ Phase 3 Adult Atopic Dermatitis clinical trial ✓ Farm to PharmTM TSXv : GSD / OTCQB : DVHGF 30
Slide 31: Stock And Financial Information
1 Stock And Financial Information CAPITAL STRUCTURE Stock Exchanges TSXv: GSD OTCQB: DVHGF TOTAL OUTSTANDING SHARES 131,266,473 Warrants 42,798,164 Stock Options 9,050,000 FULLY DILUTED SHARE CAPITAL 183,114,637 LONG-TERM DEBTS ($ MIL) Secured Loan 3.5 TOTAL 3.6 1) As of November 8, 2022 Farm to Pha
Slide 32: All the right ingredients for success!
All the right ingredients for success! Unique position Thykamine™ Faster & Near-term value Management North American outstanding economical creation solid track record botanical anti- preclinical opportunities of execution pharmaceutical inflammatory development with large drug effect with Pharma de
Slide 33: Thank You
Thank You www.groupedevonian.com TSXv: GSD OTCQB: DVHGF Farm to PharmTM TSXv : GSD / OTCQB : DVHGF 33
Devonian Health Group — Investor Presentation (December 2022) on 6ix